Delaware MPJE Practice Exam (Sample)

Study Guide



Everything you need from our exam experts!

Copyright © 2025 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain from reliable sources accurate, complete, and timely information about this product.



Questions



- 1. What is the beyond-use date (BUD) for a non-sterile compound that is a non-aqueous topical formulation?
 - A. 3 days at room temperature
 - B. 1 month refrigerated
 - C. 6 months at room temperature
 - D. 2 weeks at room temperature
- 2. What document must pharmacists in Delaware maintain regarding prescription dispensing?
 - A. Staff schedules
 - **B.** Patient medication records
 - C. Inventory lists
 - D. Annual reports
- 3. What is the primary purpose of the Delaware MPJE?
 - A. To assess the candidate's knowledge of pharmacy law and regulations specific to Delaware
 - B. To evaluate the practical skills of pharmacy candidates
 - C. To determine the financial stability of pharmacies
 - D. To review the pharmaceutical products available in Delaware
- 4. What documentation must be maintained for prescription medication in Delaware?
 - A. Only the prescriptions for medications
 - B. Patient medication records and prescriptions for at least two years
 - C. Annual summaries of prescription usage
 - D. Invoices from suppliers of medication
- 5. How long must HIPAA privacy disclosure forms be retained?
 - A. 3 years
 - B. 5 years
 - C. 6 years
 - D. 10 years

- 6. What is the minimum amount of morphine that categorizes it as a Tier 2 controlled substance?
 - A. 1 g
 - B. 2 g
 - C. 10 a
 - D. 5 g
- 7. What should a log maintained during compounding detail?
 - A. The cost of ingredients used
 - B. The identity of the person compounding and the pharmacist checks
 - C. Just the final product and its BUD
 - D. The time taken for each step of compounding
- 8. What is the quantity limit for morphine per 100 mL when combined with one or more active non-narcotic ingredients?
 - A. 100 mg
 - B. 50 mg
 - C. 30 mg
 - D. 90 mg
- 9. Are pharmacists allowed to change or modify prescriptions in Delaware?
 - A. No, it is strictly prohibited
 - B. Yes, under any circumstances
 - C. Yes, under certain circumstances with appropriate documentation
 - D. Only with the patient's verbal consent
- 10. Which drugs are required to have medication guides due to significant health concerns?
 - A. Only antidepressants
 - B. FDA-approved patient handouts for many Rxs
 - C. Vitamins and dietary supplements
 - D. Only narcotics

Answers



- 1. C 2. B 3. A 4. B 5. C 6. B 7. B 8. B 9. C 10. B



Explanations



- 1. What is the beyond-use date (BUD) for a non-sterile compound that is a non-aqueous topical formulation?
 - A. 3 days at room temperature
 - B. 1 month refrigerated
 - C. 6 months at room temperature
 - D. 2 weeks at room temperature

The beyond-use date (BUD) for a non-sterile compound that is a non-aqueous topical formulation is set at 6 months when stored at room temperature. This is based on recommendations from the United States Pharmacopeia (USP) guidelines, which provide stability parameters for compounding. Non-aqueous formulations have a longer shelf life compared to aqueous formulations because they are less susceptible to microbial contamination and degradation. The 6-month BUD is a reflection of this stability, as these compounds can maintain their integrity and potency for a longer duration when stored properly away from direct light and extreme temperatures. In contrast, choices like 3 days at room temperature or 2 weeks at room temperature are too short for non-aqueous topical formulations, which generally do not require such stringent limits. Additionally, while 1 month refrigerated may seem reasonable for certain compounds, it does not apply to this specific category of non-aqueous formulations, which have demonstrated stability at room temperature for up to 6 months.

- 2. What document must pharmacists in Delaware maintain regarding prescription dispensing?
 - A. Staff schedules
 - **B. Patient medication records**
 - C. Inventory lists
 - D. Annual reports

In Delaware, pharmacists are required to maintain patient medication records, which are critical for ensuring proper patient care and safety. Patient medication records typically include comprehensive details about a patient's medication history, including prescriptions that have been filled, dosages, and any pertinent information related to allergies or previous adverse drug reactions. This documentation is essential for pharmacists to assist in reviewing potential drug interactions, providing counseling to patients, and making informed decisions about medication therapy management. Maintaining accurate and up-to-date patient medication records helps pharmacists ensure continuity of care and promotes effective communication among healthcare providers. This is especially crucial in a state like Delaware, where pharmacists also play a role in chronic disease management and patient education. Other documents, such as staff schedules, inventory lists, and annual reports, serve different purposes within a pharmacy but do not directly relate to the practice of ensuring patient safety via understanding and managing medication regimens. Hence, they are not the primary documentation that pharmacists must maintain regarding prescription dispensing.

3. What is the primary purpose of the Delaware MPJE?

- A. To assess the candidate's knowledge of pharmacy law and regulations specific to Delaware
- B. To evaluate the practical skills of pharmacy candidates
- C. To determine the financial stability of pharmacies
- D. To review the pharmaceutical products available in Delaware

The primary purpose of the Delaware MPJE is to assess the candidate's knowledge of pharmacy law and regulations specific to Delaware. This examination is crucial because it ensures that pharmacists are well-informed about the legal framework governing pharmacy practice within the state. Understanding these laws is vital for maintaining compliance, ensuring patient safety, and providing appropriate pharmaceutical care. The examination focuses on state-specific regulations, which include licensing requirements, prescription dispensing laws, and other legal responsibilities that pharmacists must uphold to operate within Delaware. By demonstrating knowledge in these areas, candidates show that they are prepared to practice pharmacy safely and effectively within the state's legal guidelines. Other options, while they pertain to pharmacy in general, do not align with the specific objective of the MPJE. The evaluation of practical skills might be handled by a different examination process, and financial stability or product reviews are not central concerns of this particular exam. Thus, option A accurately captures the essence and intent of the Delaware MPJE.

4. What documentation must be maintained for prescription medication in Delaware?

- A. Only the prescriptions for medications
- B. Patient medication records and prescriptions for at least two years
- C. Annual summaries of prescription usage
- D. Invoices from suppliers of medication

In Delaware, the requirement to maintain patient medication records and prescriptions for at least two years is grounded in the necessity for ensuring patient safety, compliance with regulations, and the ability to track medication histories effectively. This documentation serves multiple purposes, such as enabling healthcare providers to review a patient's medication history, preventing drug interactions, and facilitating continuity of care. By maintaining comprehensive records, pharmacists and healthcare professionals can ensure they are making well-informed decisions regarding a patient's treatment plan. Furthermore, this practice aligns with regulatory standards set forth to monitor medication usage and assist in any inquiries regarding patient care or medication errors that may arise. Keeping both patient medication records and prescriptions for this duration is crucial for maintaining transparency and accountability within the healthcare system. The other options do not encompass the full range of necessary documentation. For instance, only maintaining prescriptions alone would lack the integral information found in complete patient medication records, which would encompass broader details of a patient's treatment and medication regime.

- 5. How long must HIPAA privacy disclosure forms be retained?
 - A. 3 years
 - B. 5 years
 - C. 6 years
 - D. 10 years

The requirement to retain HIPAA privacy disclosure forms is set forth in the HIPAA Privacy Rule, which mandates that covered entities must retain documentation for six years from the date of its creation or the date when it last was in effect, whichever is later. This retention period ensures that entities are compliant with federal regulations and can provide necessary documentation to demonstrate their adherence to privacy practices and safeguards regarding patient information. Organizations must keep these records accessible for both internal audits and potential oversight by regulatory bodies, making the six-year retention period essential for proper compliance with HIPAA regulations. Adhering to this timeline helps organizations maintain accountability and supports individuals' rights to privacy concerning their health information.

- 6. What is the minimum amount of morphine that categorizes it as a Tier 2 controlled substance?
 - A. 1 g
 - B. 2 g
 - C. 10 q
 - D. 5 g

The classification of morphine as a Tier 2 controlled substance is based on specific federal and state regulations regarding the weight of the substance. In Delaware, controlled substances are categorized into tiers based on their potential for abuse and the amount that is considered to be significant for legal purposes. In this context, a minimum amount of 2 grams of morphine qualifies it as a Tier 2 controlled substance. This means that possessing, distributing, or manufacturing this quantity of morphine triggers stricter legal ramifications under controlled substance laws. The determination of 2 grams reflects a threshold intended to differentiate between lesser quantities that may be seen as personal use and those quantities that indicate a higher risk of abuse or trafficking. Understanding the tiered system is critical, as it informs pharmacists, law enforcement, and healthcare providers about the level of control and regulations that apply to certain substances.

7. What should a log maintained during compounding detail?

- A. The cost of ingredients used
- B. The identity of the person compounding and the pharmacist checks
- C. Just the final product and its BUD
- D. The time taken for each step of compounding

The log maintained during compounding should include the identity of the person compounding and the pharmacist who checks the work. This is essential for maintaining accountability and ensuring patient safety. Documenting who performed each step in the compounding process allows for traceability if there are any questions about the quality or safety of the compounded medication. Furthermore, having the pharmacist who verifies the compounding details also contributes to a double-check system that minimizes the risk of errors. Accurate record-keeping in compounding is crucial for regulatory compliance and quality assurance. This log serves as a reference for future audits and helps ensure that proper procedures were followed during the compounding process. The inclusion of the compounding personnel's identity also aids in tracking training and competencies. While other options might seem relevant, they do not address the fundamental aspect of accountability and verification that is critical in compounding pharmacy practice.

- 8. What is the quantity limit for morphine per 100 mL when combined with one or more active non-narcotic ingredients?
 - A. 100 mg
 - **B.** 50 mg
 - C. 30 mg
 - D. 90 mg

When considering the quantity limit for morphine when combined with one or more active non-narcotic ingredients in a liquid preparation, the quantity recognized for morphine is 50 mg per 100 mL. This regulation falls under the classification of certain combinations of narcotics and non-narcotics, which are subject to specific federal and state guidelines. In these combinations, the presence of active non-narcotic ingredients is intended to mitigate the potential for abuse of the narcotic component and to provide therapeutic benefits. The established limit of 50 mg of morphine per 100 mL helps maintain a balance between effective pain management and minimizing the risk for misuse or addiction. Understanding this limit is important for compliant prescription practices, especially in settings where both narcotic and non-narcotic medications are used concurrently. Familiarity with such regulatory details aids healthcare professionals in making informed decisions regarding patient care while adhering to legal standards.

9. Are pharmacists allowed to change or modify prescriptions in Delaware?

- A. No, it is strictly prohibited
- B. Yes, under any circumstances
- C. Yes, under certain circumstances with appropriate documentation
- D. Only with the patient's verbal consent

In Delaware, pharmacists have the ability to change or modify prescriptions under specific circumstances, provided that they adhere to certain guidelines and maintain appropriate documentation. This flexibility is essential as it allows pharmacists to optimize patient care, address issues such as dosage adjustments, changes in formulation, or substitution of prescribed medications for therapeutic equivalence. The requirement for proper documentation ensures that any modifications made are well-recorded, which maintains the integrity of the patient's medication profile and can be reviewed for future reference, thus promoting safety and accountability in the medication management process. This practice aligns with the broader scope of pharmacy practice, which empowers pharmacists to act as medication experts in collaboration with healthcare providers to enhance treatment outcomes for patients. Other options suggest either a complete prohibition against modifications or an overly broad allowance for any modifications without consideration of the clinical scenario and documentation requirements, which do not reflect the regulatory framework governing pharmacy practice in Delaware.

10. Which drugs are required to have medication guides due to significant health concerns?

- A. Only antidepressants
- B. FDA-approved patient handouts for many Rxs
- C. Vitamins and dietary supplements
- **D.** Only narcotics

The correct choice highlights the requirement for FDA-approved patient handouts, known as medication guides, for a wide range of prescription medications that pose significant health concerns. Medication guides are designed to ensure that patients receive important information about the drugs they are taking, including potential risks, benefits, and safe usage, which can help mitigate adverse effects and promote optimal therapeutic outcomes. Medication guides are typically mandated for certain classes of drugs, including but not limited to antidepressants, antipsychotics, anti-seizure medications, and other treatments that come with serious warnings. The requirement is part of the Food and Drug Administration's risk mitigation strategies, ensuring that patients are properly informed. In contrast, the options that specify only certain classes of drugs—such as antidepressants, narcotics, or mention vitamins and dietary supplements—do not encompass the broader range of medications that may necessitate a medication guide. Vitamins and dietary supplements, for instance, are generally not subject to the same regulations as prescription medications and usually do not require such detailed patient information, whereas narcotics are just one category within a more extensive list that may have medication guides due to their associated risks.